Danimer Scientific Valuation
Is DNMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DNMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DNMR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DNMR's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DNMR?
Key metric: As DNMR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is DNMR's PS Ratio? | |
|---|---|
| PS Ratio | 0.5x |
| Sales | US$37.43m |
| Market Cap | US$18.51m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10.6x |
| Enterprise Value/EBITDA | -7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does DNMR's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.6x | ||
NNUP Nocopi Technologies | 10x | n/a | US$18.4m |
FSI Flexible Solutions International | 1.3x | 14.9% | US$49.2m |
ALTO Alto Ingredients | 0.1x | 3.1% | US$106.5m |
NMGX Nano Magic | 3.1x | n/a | US$7.9m |
DNMR Danimer Scientific | 0.5x | 47.8% | US$18.5m |
Price-To-Sales vs Peers: DNMR is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (3.6x).
Price to Sales Ratio vs Industry
How does DNMR's PS Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Sales vs Industry: DNMR is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Chemicals industry average (1.4x).
Price to Sales Ratio vs Fair Ratio
What is DNMR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | 0.2x |
Price-To-Sales vs Fair Ratio: DNMR is expensive based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$6.13 | US$32.00 +422.0% | 35.4% | US$40.00 | US$16.00 | n/a | 3 |
| Nov ’25 | US$13.32 | US$32.00 +140.2% | 35.4% | US$40.00 | US$16.00 | n/a | 3 |
| Oct ’25 | US$17.75 | US$34.00 +91.6% | 30.6% | US$40.00 | US$16.00 | n/a | 4 |
| Sep ’25 | US$15.02 | US$43.20 +187.7% | 47.7% | US$80.00 | US$16.00 | n/a | 5 |
| Aug ’25 | US$14.84 | US$56.40 +280.0% | 35.6% | US$80.00 | US$32.00 | n/a | 5 |
| Jul ’25 | US$22.50 | US$56.40 +150.7% | 35.6% | US$80.00 | US$32.00 | n/a | 5 |
| Jun ’25 | US$31.19 | US$56.40 +80.8% | 35.6% | US$80.00 | US$32.00 | n/a | 5 |
| May ’25 | US$29.50 | US$60.40 +104.7% | 27.3% | US$80.00 | US$40.00 | n/a | 5 |
| Apr ’25 | US$42.00 | US$88.80 +111.4% | 41.1% | US$140.00 | US$40.00 | n/a | 5 |
| Mar ’25 | US$50.80 | US$106.80 +110.2% | 28.9% | US$140.00 | US$64.00 | n/a | 5 |
| Feb ’25 | US$25.97 | US$106.80 +311.2% | 28.9% | US$140.00 | US$64.00 | n/a | 5 |
| Jan ’25 | US$40.80 | US$106.80 +161.8% | 28.9% | US$140.00 | US$64.00 | n/a | 5 |
| Dec ’24 | US$46.00 | US$124.00 +169.6% | 20.8% | US$150.00 | US$80.00 | n/a | 5 |
| Nov ’24 | US$53.60 | US$176.00 +228.4% | 33.1% | US$280.00 | US$110.00 | US$13.32 | 5 |
| Oct ’24 | US$82.80 | US$188.00 +127.1% | 31.8% | US$280.00 | US$110.00 | US$17.75 | 5 |
| Sep ’24 | US$76.00 | US$184.00 +142.1% | 29.3% | US$260.00 | US$110.00 | US$15.02 | 5 |
| Aug ’24 | US$101.60 | US$212.00 +108.7% | 36.5% | US$320.00 | US$110.00 | US$14.84 | 5 |
| Jul ’24 | US$95.20 | US$212.00 +122.7% | 36.5% | US$320.00 | US$110.00 | US$22.50 | 5 |
| Jun ’24 | US$120.40 | US$232.50 +93.1% | 26.8% | US$320.00 | US$160.00 | US$31.19 | 4 |
| May ’24 | US$117.20 | US$222.50 +89.8% | 22.1% | US$280.00 | US$160.00 | US$29.50 | 4 |
| Apr ’24 | US$138.00 | US$190.00 +37.7% | 21.7% | US$260.00 | US$160.00 | US$42.00 | 4 |
| Mar ’24 | US$96.00 | US$245.00 +155.2% | 55.5% | US$480.00 | US$160.00 | US$50.80 | 4 |
| Feb ’24 | US$94.00 | US$245.00 +160.6% | 55.5% | US$480.00 | US$160.00 | US$25.97 | 4 |
| Jan ’24 | US$71.60 | US$245.00 +242.2% | 55.5% | US$480.00 | US$160.00 | US$40.80 | 4 |
| Dec ’23 | US$92.80 | US$245.00 +164.0% | 55.5% | US$480.00 | US$160.00 | US$46.00 | 4 |
| Nov ’23 | US$112.00 | US$300.00 +167.9% | 37.4% | US$480.00 | US$180.00 | US$53.60 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Trinseo
US$117.5m
Operates as a specialty material solutions provider in the United States, Europe, the Asia-Pacific, and internationally.
TSE
US$3.32
7D
-8.3%
1Y
-48.8%
CMOC Group
HK$167.3b
Engages in the mining, beneficiation, smelting, and refining of base and rare metals.
CMCL.F
HK$0.76
7D
0%
1Y
37.8%
Chemtrade Logistics Income Fund
CA$1.4b
Offers industrial chemicals and services in Canada, the United States, and South America.
CGIF.F
CA$8.30
7D
5.2%
1Y
31.5%